24.10.2022 • News

Ineos to Take Ashta Chemicals from Bigshire Mexico

Ineos Enterprises has agreed to acquire Ashta Chemicals from Bigshire Mexico for an undisclosed sum. The deal that includes a 100,000 kg/y potassium hydroxide (KOH) and a 65,000 t/y chlorine plant, is targeted to close before the end of 2022, subject to regulatory approvals.

Ashta Chemicals manufactures and markets chlorine and a range of potassium-based chemicals to a wide variety of end use markets including liquid fertilizers, runway deicers, food ingredients, pharmaceuticals and agricultural applications. The company employs around 110 people at its Ohio site, close to Ineos’ pigments operations, where it operates a recently commissioned membrane cell technology chlor-alkali unit.

Ashley Reed, CEO of Ineos Enterprises – which runs the chemical group’s intermediates business – said Ashta is “an excellent strategic fit” for the long-term local supply and use of chlorine between the two companies. The buy also will add “a well-established and respected” North American potassium hydroxide business to the Ineos portfolio.

© ytonn/Unsplash
© ytonn/Unsplash

Bigshire Mexico’s chief financial officer, Ruy Zavala, said Ashta has undertaken “significant investments” under his company’s ownership, most notably the construction and commissioning of the modern membrane cell chlor-alkali plant that utilizes Ineos’ Bichlor technology.  

Zavala added that Bigshire believes the next phase of Ashta’s development can be “well progressed” as part of Ineos, projecting that “the complementary strategic fit” to be created will further improve the long-term sustainability of the company and its employees.   

Author: Dede Williams, Freelance Journalist

Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read